Skip to content
ClinCalc Pro
Menu
Calculators Drugs Pathways AI Dx Donate Get the App
3rd-generation EGFR tyrosine-kinase inhibitor

Lazertinib (Specialist drug)

Brand names: Lazcluze

Lazertinib is an oral third-generation EGFR tyrosine kinase inhibitor used as a specialist treatment for EGFR-mutated non-small cell lung cancer, including the T790M resistance mutation. It is taken once daily under oncology supervision.

Dosing — being independently re-sourced

ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.

Clinical monograph

How it works

It irreversibly and selectively inhibits common activating EGFR mutations and the T790M resistance mutation while sparing wild-type EGFR, blocking tumour growth signalling.

Prescribing in practice

  • Interstitial lung disease and pneumonitis are serious risks; withhold and investigate any new or worsening respiratory symptoms.
  • QT prolongation, rash, paronychia and gastrointestinal effects can occur and require monitoring.
  • Confirm the relevant EGFR mutation before use and review concurrent medicines for interactions.

Monitoring

Monitor for respiratory symptoms suggestive of pneumonitis, and check ECG and electrolytes where clinically indicated.

Counselling the patient

  • Report new or worsening breathlessness, cough or fever promptly.
  • Report troublesome rash or nail changes so they can be managed early.
  • Tell the team about all other medicines before starting.

Evidence & guidelines

Lazertinib has been studied as monotherapy and in combination for EGFR-mutated non-small cell lung cancer in clinical trials.

Reference: SmPC; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).

Related

Curated clinical cross-links plus same-class fallbacks.

Calculators
Drugs
Pathways